The role of lifestyle change in the prevention and treatment of NAFLD

Current Pharmaceutical Design

Volumn 19, Issue 29, 2013, Pages 5270-5279

  Centis, Elena ^a   Marzocchi, Rebecca ^a   Suppini, Alessandro ^b   Dalle Grave, Riccardo ^c   Villanova, Nicola ^a   Hickman, Ingrid J ^b,d   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Villa Garda Hospital   (Italy)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Behavior therapy; Cardiovascular disease; Metabolic syndrome; Nonalcoholic fatty liver disease; Physical activity; Prevention; Treatment

Indexed keywords

AEROBIC EXERCISE; ARTICLE; BEHAVIOR THERAPY; DIABETES MELLITUS; DIET RESTRICTION; DOCTOR PATIENT RELATION; FITNESS; FOOD INTAKE; HEALTH CARE ACCESS; HUMAN; INTERNET; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOBILE PHONE; NONALCOHOLIC FATTY LIVER; NUTRIENT; OBESITY; OCCUPATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESISTANCE TRAINING; SEDENTARY LIFESTYLE; WEIGHT REDUCTION;

EID: 84897584579     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128130304     Document Type: Article

References (106)

1. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. J Hepatol 2012; 56: 255-66.
2. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011: CD003619.
3. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007; 56: 1760-9.
4. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
5. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005; 41: 64-71.
6. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a sevenyear prospective follow-up. J Hepatol 2012; 56: 1145-51.
7. Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR American journal of roentgenology 2009; 192: 909-14.
8. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004; 49: 1578-83.
9. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006; 25: 816-23.
10. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-16.
11. Toshimitsu K, Matsuura B, Ohkubo I, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007; 23: 46-52.
12. Petit JM, Guiu B, Masson D, et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: E430-6.
13. Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 1360-9.
14. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki- Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.
15. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight non-diabetic subjects. J Clin Endocrinol Metab 2005; 90: 2804-9.
16. Prentice AM, Jebb SA. Fast foods, energy density and obesity: a possible mechanistic link. Obes Rev 2003; 4: 187-94.
17. Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut 2008; 57: 568-70.
18. Pereira MA, Kartashov AI, Ebbeling CB, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005; 365: 36-42.
19. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005; 63: 133-57.
20. Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007; 86: 899-906.
21. Schulze MB, Manson JE, Ludwig DS, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004; 292: 927-34.
22. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-71.
23. Newby PK, Muller D, Hallfrisch J, Qiao N, Andres R, Tucker KL. Dietary patterns and changes in body mass index and waist circumference in adults. Am J Clin Nutr 2003; 77: 1417-25.
24. Freedman ND, Cross AJ, McGlynn KA, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst 2010; 102: 1354-65.
25. Polesel J, Talamini R, Montella M, La Vecchia C, Serraino D, Franceschi S. Re: Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst 2011; 103: 446-8.
26. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-7.
27. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. American journal of physiology Gastrointestinal and liver physiology 2008; 295: G987-95.
28. Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008; 47: 1158-66.
29. Erlichman J, Kerbey AL, James WP. Physical activity and its impact on health outcomes. Paper 2: Prevention of unhealthy weight gain and obesity by physical activity: an analysis of the evidence. Obes Rev 2002; 3: 273-87.
30. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS, Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325: 147-52.
31. Di Loreto C, Fanelli C, Lucidi P, et al. Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care 2003; 26: 404-8.
32. Di Loreto C, Fanelli C, Lucidi P, et al. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care 2005; 28: 1295-302.
33. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286: 1218-27.
34. Keating SE, Hackett DA, George J, Johnson NA. Exercise and nonalcoholic fatty liver disease: A systematic review and metaanalysis. J Hepatol 2012; 57: 157-66.
35. Lawlor DA, Sattar N, Smith GD, Ebrahim S. The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. American journal of epidemiology 2005; 161: 1081-8.
36. Perseghin G, Lattuada G, De Cobelli F, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007; 30: 683-8.
37. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006; 130: 2023-30.
38. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-8.
39. Sreenivasa Baba C, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21: 191-8.
40. Newton JL, Jones DE, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-13.
41. Irwin ML, Ainsworth BE, Mayer-Davis EJ, Addy CL, Pate RR, Durstine JL. Physical activity and the metabolic syndrome in a triethnic sample of women. Obes Res 2002; 10: 1030-7.
42. Wong SL, Katzmarzyk P, Nichaman MZ, Church TS, Blair SN, Ross R. Cardiorespiratory fitness is associated with lower abdominal fat independent of body mass index. Medicine and science in sports and exercise 2004; 36: 286-91.
43. Johnson NA, Keating SE, George J. Exercise and the liver: implications for therapy in fatty liver disorders. Semin Liver Dis 2012; 32: 65-79.
44. Capristo E, Miele L, Forgione A, et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005; 9: 265-8.
45. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-8.
46. Sato F, Tamura Y, Watada H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007; 92: 3326-9.
47. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-9.
48. Okita M, Hayashi M, Sasagawa T, et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001; 17: 542-7.
49. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
50. Suzuki A, Lindor K, St Sauver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43: 1060-6.
51. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999; 92: 73-9.
52. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 3191-6.
53. Browning JD, Davis J, Saboorian MH, Burgess SC. A low- carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. Hepatology 2006; 44: 487-8.
54. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-12.
55. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-8.
56. Ibanez J, Izquierdo M, Arguelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005; 28: 662-7.
57. Tsuzuku S, Kajioka T, Endo H, Abbott RD, Curb JD, Yano K. Favorable effects of non-instrumental resistance training on fat distribution and metabolic profiles in healthy elderly people. Eur J Appl Physiol 2007; 99: 549-55.
58. Ballor DL, Keesey RE. A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in males and females. Int J Obes 1991; 15: 717-26.
59. Chen SM, Liu CY, Li SR, Huang HT, Tsai CY, Jou HJ. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. J Chin Med Assoc 2008; 71: 551-8.
60. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
61. Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169-75.
62. Perri MG, Corsica JA. Improving the maintenance of weight lost in behavioral treatment of obesity. In: Wadden TA, Stunkard AJ, editors. Handbook of Obesity Treatment. New York, N.Y.: The Guildford Press; 2002. p. 357-79.
63. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
64. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
65. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
66. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 2003; 26: 36-47.
67. Miltenberger RG. Behavior Modification: Principle and Procedures. Pacific Grove (CA.): Brooke/Cole Publ. Co.; 1994.
68. Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? J Am Diet Assoc 2007; 107: 92-9.
69. Wadden TA, Butryn ML. Behavioral treatment of obesity. Endocrinol Metab Clin North Am 2003; 32: 981-1003, x.
70. Wing RR. Behavioral approaches to the treatment of obesity. In: Bray GA, Bouchard C, editors. Handbook of Obesity: Clinical Applications, 2nd Edition ed. New York: Marcel Dekker, Inc.; 2004. p. 147-67.
71. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT. Understanding and preventing relapse. Am Psychol 1986; 41: 765-82.
72. Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ, editors. Handbook of Obesity Treatment. New York: The Guildford Press; 2002. p. 301-16.
73. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
74. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy in nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008; 47: 746-54.
75. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
76. Hickman IE, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-9.
77. Osland EJ, Powell EE, Banks M, Jonsson JR, Hickman IJ. Obesity management in liver clinics: translation of research into clinical practice. J Gastroenterol Hepatol 2007; 22: 504-9.
78. Moscatiello S, Di Luzio R, Bugianesi E, et al. Cognitive-behavioral treatment of non-alcoholic fatty liver disease: a propensity scoreadjusted observational study. Obesity (Silver Spring) 2011; 19: 763-70.
79. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007; 30: 1374-83.
80. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
81. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50: 68-76.
82. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-81.
83. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Controlled clinical trials 2003; 24: 610-28.
84. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-6.
85. Jakicic JM, Jaramillo SA, Balasubramanyam A, et al. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond) 2009; 33: 305-16.
86. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156-63.
87. Krakoff J, Clark JM, Crandall JP, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the Diabetes Prevention Program. Obesity (Silver Spring) 2010; 18: 1762-7.
88. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165-71.
89. Stalonas PM, Perri MG, Kerzner AB. Do behavioral treatments of obesity last? A five-year follow-up investigation. Addict Behav 1984; 9: 175-83.
90. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989; 13 Suppl 2: 39-46.
91. Wing RR, Phelan S. Behavioral treatment of obesity: strategies to improve outcome and predictors of success. In: Eckel RH, editor. Obesity: Mechanisms and Clinical Management. Philadelphia: Lippincott, Williams & Wilkins; 2003. p. 415-35.
92. Dalle Grave R, Calugi S, Centis E, Marzocchi R, El Ghoch M, Marchesini G. Lifestyle modification in the management of metabolic syndrome: achievements and challenges. DOMSTT 2010; 3: 1-13.
93. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003; 27: 537-49.
94. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr 2003; 78: 684-9.
95. Perri MG, Sears SF, Jr., Clark JE. Strategies for improving maintenance of weight loss. Toward a continuous care model of obesity management. Diabetes Care 1993; 16: 200-9.
96. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
97. Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring, Md 2011; 19: 1987-98.
98. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res 2004; 12 Suppl: 151S-62S.
99. National Institutes of Health, National Heart Lung and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD.: National Institutes of Health; 2000.
100. Dalle Grave R, Calugi S, Centis E, El Ghoch M, Marchesini G. Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity. Journal of obesity 2011; 2011: 348293.
101. U.S. Department of Health and Human Services, U.S. Department of Agriculture. Dietary Guidelines for Americans, 2005. 6th Ed. Washington, DC: U.S. Government Printing Office; 2005.
102. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
103. Cooper Z, Fairburn CG. A new cognitive behavioural approach to the treatment of obesity. Behav Res Ther 2001; 39: 499-511.
104. Stahre L, Hallstrom T. A short-term cognitive group treatment program gives substantial weight reduction up to 18 months from the end of treatment. A randomized controlled trial. Eat Weight Disord 2005; 10: 51-8.
105. Werrij MQ, Jansen A, Mulkens S, Elgersma HJ, Ament AJ, Hospers HJ. Adding cognitive therapy to dietetic treatment associated with less relapse in obesity. J Psychosom Res 2009; 67: 315-24.
106. Brownell KD, Horgen KB. Food Fight: The Inside Story of the Food Industry. New York: McGraw-Hill; 2004.